Get the Daily Brief
Latest Biotech News
Long‑read sequencing: PacBio cuts genome costs with reusable SMRT cells
Pacific Biosciences unveiled a program enabling reuse of SMRT cell consumables and launched a new Sprq‑Nx chemistry that raises output and adds 5‑hydroxymethylcytosine detection. PacBio says...
In vivo programming and LNPs: Create Medicines expands, startups raise LNP capital
Myeloid Therapeutics rebranded as Create Medicines and broadened its in‑vivo immune programming strategy beyond myeloid cells to include T and NK cells using mRNA‑LNP platforms, aiming for...
Clinical genomics speeds to the bedside — hours‑long WGS and rapid RNA‑Seq services
Boston Children’s Hospital, Broad Clinical Labs and Roche Sequencing Solutions achieved a new record for ultra‑fast human whole‑genome sequencing optimized for NICU diagnostics, compressing...
ALS diagnostics and research: blood test emerges, molecular insights deepen
UCLA Health researchers reported a blood test that detects ALS rapidly by measuring circulating cell‑free DNA (cfDNA) signatures, offering a potential noninvasive diagnostic adjunct for earlier...
mRNA supply chain upgrades: cellulose membrane purification and CDMO capacity in India
Researchers at Rensselaer Polytechnic Institute developed a regenerated cellulose (RC) membrane with peptide ligands that outperformed chromatography columns for mRNA purification, offering...
Public‑health upheaval: CDC cuts and exodus from FDA leadership unsettle agencies
Mass layoffs and leadership departures at the US Centers for Disease Control and Prevention have culled an estimated quarter of the workforce this year, according to union tallies, affecting...
Novo Nordisk Licenses Omeros’ MASP‑3 drug: $2.1B deal
Novo Nordisk struck a definitive asset purchase and license agreement with Omeros for zaltenibart, an experimental MASP‑3 inhibitor, in a deal worth up to $2.1 billion including $340 million in...
Tubulis Raises €308M Series C — ADC program expansion
Antibody‑drug conjugate specialist Tubulis closed a large Series C financing—reported at roughly €308 million (about $356 million)—to accelerate clinical development of TUB‑040 and its ADC...
Pelage Collects $120M... Phase III for hair‑loss gel set
Pelage Pharmaceuticals closed an oversubscribed $120 million Series B to advance PP‑405, a topical regenerative small molecule intended to reactivate dormant hair follicle stem cells, into a...
Kailera Nets $600M Series B: Dual‑target obesity shot moves to Phase 3
Kailera Therapeutics closed a $600 million Series B led by Bain Capital Private Equity to support global Phase‑3 trials of KAI‑9531, a weekly injectable targeting the same dual receptor axis as...
Lilly Defends Oral GLP‑1: New data bolster orforglipron
Eli Lilly reported two additional late‑stage diabetes trial wins for orforglipron, an oral GLP‑1 receptor agonist, including superiority versus AstraZeneca’s Farxiga in glycemic control in Type 2...
PacBio Lowers Genome Cost: Reusable consumables cut prices to <$300
Pacific Biosciences announced a program to allow select customers to reuse costly SMRT cell consumables and launched a new sequencing chemistry (Sprq‑Nx) that increases output and adds...
Lila Sciences Raises $350M Series A: Nvidia Joins as investor
Flagship‑backed Lila Sciences expanded its Series A with a $115 million extension after an initial $235 million close, bringing total Series A proceeds to $350 million; the extension included...
Create Medicines Rebrands: Expands in‑vivo mRNA‑LNP immune programming
Myeloid Therapeutics announced a rebrand to Create Medicines and unveiled a strategic expansion beyond in‑vivo myeloid programming to include T‑cell and NK‑cell programming using its mRNA‑LNP...
New RC membrane outperforms columns: faster mRNA purification
Researchers at Rensselaer Polytechnic Institute reported a regenerated cellulose (RC) membrane with peptide ligands that outperformed commercial chromatography columns for purifying mRNA...
Gene therapy restores immunity in ADA‑SCID children: multicenter success
A collaborative gene‑therapy program led by UCLA, University College London and Great Ormond Street Hospital reported durable restoration of immune function in children with adenosine deaminase...
Kailera raises $600M – Prepares Zepbound‑like obesity shot for global phase 3
Kailera Therapeutics closed a $600 million Series B to fund global Phase 3 testing of KAI‑9531, a weekly injectable that targets the same receptors as Eli Lilly’s Zepbound. Bain Capital Private...
Pelage bags $120M – Topical regenerative gel moves to Phase 3
Pelage Pharmaceuticals raised $120 million in a Series B to advance its regenerative, topical gel designed to reactivate dormant hair‑follicle stem cells into Phase 3 trials next year. The round...
Tubulis raises $361M – ADC developer expands clinical footprint
Tubulis, a Munich‑based antibody‑drug conjugate (ADC) developer, closed a roughly $361 million financing to accelerate clinical testing of its lead ADCs, including TUB‑040 in ovarian and...
Novo Nordisk shells out up to $2.1B — Buys Omeros’ MASP‑3 program
Novo Nordisk agreed to acquire Omeros’ MASP‑3 inhibitor programme in a transaction worth up to $2.1 billion to advance zaltenibart, a candidate for paroxysmal nocturnal hemoglobinuria (PNH) and...